BioInvent & Cancer Research Technology Announce Oncology Collaboration

A new collaboration between BioInvent, Cancer Research Technology and Queen Mary, University of London will aim to speed up the discovery and development of new cancer treatments.

BioInvent International AB and Cancer Research Technology, the commercial arm of the charity Cancer Research UK, have announced a new collaboration with Queen Mary, University of London to identify therapeutic antibodies in oncology.

BioInvent is a research-based pharmaceutical company that specialises in developing antibody drugs for thrombosis, cancer and atherosclerosis.

Alongside Cancer Research UK-funded scientists at Queen Mary, the company will apply its functional approach to therapeutic antibody discovery - F.I.R.S.T - to identify new therapeutic targets.

The project will be led by Dr Thorsten Hagemann, a senior research fellow at Cancer Research UK.